| Literature DB >> 26198912 |
Michael J Turner1, Petti T Pang2, Nathalie Chretien2, Evis Havari2, Michael J LaMorte2, Julian Oliver3, Nilesh Pande2, Elizabeth Masterjohn4, Karen Carter4, David Reczek4, William Brondyk4, Bruce L Roberts2, Johanne M Kaplan2, William M Siders2.
Abstract
Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A single course of anti-muCD52 provided a therapeutic benefit accompanied by a reduction in the frequency of autoreactive T lymphocytes and production of pro-inflammatory cytokines. Examination of the CNS revealed a decrease in infiltrating lymphocytes, demyelination and axonal loss. Electrophysiological assessment showed preservation of axonal conductance in the spinal cord. These findings suggest that anti-CD52 therapy may help preserve CNS integrity.Entities:
Keywords: Alemtuzumab; CD52; Experimental autoimmune encephalomyelitis; Mouse; Multiple sclerosis
Mesh：
Substances：
Year: 2015 PMID： 26198912 DOI： 10.1016/j.jneuroim.2015.05.018
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478